| | Rank | Article | First author | IF | Altmetric.com Attention Score | No. of citations |
| | 1 | Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial, Lancet, 2016, 388, 576. | Atkins H. L. | 53.254 | 1302 | 68 | | 2 | Nuclear receptor NR1H3 in familial multiple sclerosis, Neuron, 201692, 555. | Wang Z. | 14.318 | 1226 | 24 | | 3 | Ocrelizumab versus placebo in primary progressive multiple sclerosis, N Engl J Med, 2017, 376, 209. | Mantalban X. | 79.258 | 975 | 220 | | 4 | Time to wake up and smell the coffee? Coffee consumption and multiple sclerosis, J Neurol Neurosurg Psychiatry, 2016, 87, 453. | Wijnands J. M. | 7.144 | 951 | 1 | | 5 | Breastfeeding, ovulatory years, and risk of multiple sclerosis, Neurology, 2017, 89, 563. | Langer-Gould A. | 7.609 | 787 | 5 | | 6 | Alemtuzumab improves preexisting disability in active relapsing-remitting multiple sclerosis patients, Neurology, 2016, 87, 1985. | Giovannoni G. | 7.609 | 689 | 17 | | 7 | Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study, Lancet, 2018, 391, 1263. | Kappos L. | 53.254 | 659 | 16 | | 8 | A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, 2010, 362, 416. | Giovannoni G. | 79.258 | 649 | 332 | | 9 | Pediatric multiple sclerosis, Neurology, 2016, 87, S74. | Waldman A. | 7.609 | 635 | 15 | | 10 | Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, Lancet, 2012, 380, 1829. | Coles A. J. | 53.254 | 623 | 506 | | 11 | Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in multiple sclerosis, Neurology, 2016, 87, 1464. | Arnold D. L. | 7.609 | 615 | 6 | | 12 | Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial, Lancet Neurol, 2014, 13, 257. | Leist T. P. | 27.138 | 609 | 50 | | 13 | Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system, JAMA, 2015, 313, 54. | Scheller N. M. | 47.661 | 593 | 76 | | 14 | Multiple Sclerosis, N Engl J Med, 2018, 378, 169. | Reich D. S. | 79.258 | 572 | 31 | | 15 | Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial, Lancet Neurol, 2016, 15, 373. | Cohen J. A. | 27.138 | 511 | 38 | | 16 | Long-term outcomes after autologous hematopoietic stem cell transplantation for Multiple sclerosis, JAMA Neurol, 2017, 74, 459. | Muraro P. A. | 11.46 | 474 | 30 | | 17 | Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis, N Engl J Med, 2016, 376, 221. | Hauser S. L. | 79.258 | 469 | 167 | | 18 | Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial, Lancet Neurol, 2016, 15, 35. | Voskuhl R. R. | 27.138 | 463 | 49 | | 19 | Predisposing role of vitamin D receptor (VDR) polymorphisms in the development of multiple sclerosis: a case-control study, J Neurol Sci, 2016, 367, 148. | Abdollahzadeh R. | 2.448 | 436 | 7 | | 20 | Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with multiple sclerosis and their spouse caregivers, J Neurol Sci, 2013, 330, 71. | Parisé H. | 2.448 | 435 | 20 | | 21 | Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial, Lancet, 2014, 383, 2213. | Chataway J. | 53.254 | 417 | 162 | | 22 | Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis, Neuropharmacology, 2015, 110, 644. | Sedel F. | 4.249 | 412 | 44 | | 23 | Anti-spasticity agents for multiple sclerosis, Cochrane database Sys Rev, 2003, (4), CD001332. | Shakespeare D. | 6.754 | 408 | 137 | | 24 | The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?, Neurology, 2015, 84, 2185. | Hartung D. M. | 7.609 | 403 | 84 | | 25 | Trial of minocycline in a clinically isolated syndrome of multiple sclerosis, N Engl J Med, 2017, 376, 2122. | Metz L. M. | 79.258 | 388 | 23 | | 26 | Efficacy and safety of extracranial vein angioplasty in multiple sclerosis: a randomized clinical trial, JAMA Neurol, 2017, 75, 35. | Zamboni P. | 11.46 | 379 | 8 | | 27 | High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies, J Neurol Neurosurg, Psychiatry, 2016, 87, 454. | Hedström A. K. | 7.144 | 367 | 18 | | 28 | Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort, JAMA Neurol, 2016, 73, 515. | Munger K. L. | 11.46 | 366 | 41 | | 29 | Diet quality is associated with disability and symptom severity in multiple sclerosis, Neurology, 2018, 90, e1. | Fitzgerald K. C. | 7.609 | 357 | 5 | | 30 | Effects of physical comorbidities on disability progression in multiple sclerosis, Neurology, 2018, 90, e419. | Zhang T. | 7.609 | 355 | 3 | | 31 | Vitamin D and risk of multiple sclerosis: A Mendelian randomization study, PLoS Med, 2015, 12, e1001866. | Mokry LE | 11.675 | 347 | 110 | | 32 | Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases, JAMA Neurol, 2014, 71, 1506. | Langer-Gould A. | 11.46 | 344 | 58 | | 33 | Concussion in adolescence and risk of multiple sclerosis, Ann Neurol, 2017, 82, 554. | Montgomery S. | 10.244 | 341 | 6 | | 34 | High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): A 3-year interim report, JAMA Neurol, 2015, 72, 159. | Nash R. A. | 11.46 | 322 | 73 | | 35 | Smoked cannabis for spasticity in multiple sclerosis: A randomised, placebo-controlled trial, CMAJ, 2012, 184, 1143. | Corey-Bloom J. | 6.21 | 319 | 84 | | 36 | Cladribine to treat relapsing forms of multiple sclerosis, Neurotherapeutics, 2017, 14, 874. | Giovannoni G. | 5.719 | 317 | 2 | | 37 | Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis, Neurology, 2016, 86, 382. | Sotirchos E. S. | 7.609 | 302 | 45 | | 38 | Neonatal vitamin D status and risk of multiple sclerosis A population-based case-control study, Neurology, 2017, 88, 44. | Nielsen N. M. | 7.609 | 297 | 24 | | 39 | Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis, JAMA Neurol, 2015, 313, 275. | Burt R. K. | 11.46 | 296 | 66 | | 40 | Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, 2015, 373, 1418. | Kappos L. | 79.258 | 295 | 132 | | 41 | 25-Hydroxyvitamin D deficiency and risk of multiple sclerosis among women in the Finnish Maternity cohort, Neurology, 2017, 89, 1578. | Munger K. L. | 7.609 | 292 | 5 | | 42 | Sun exposure over the life course and associations with multiple sclerosis, Neurology, 2018, 90, e1191. | Tremlett H. | 7.609 | 286 | —a | | 43 | Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial, Lancet, 2017, 90, 2481. | Green A. J. | 53.254 | 282 | 34 | | 44 | Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis, J Neurol Neurosurg Psychiatry, 2016, 87, 1343. | Tao C. | 7.144 | 276 | 10 | | 45 | No association between dietary sodium intake and the risk of multiple sclerosis, Neurology, 2017, 89, 1322. | Cortese M. | 7.609 | 260 | 7 | | 46 | Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of neurology, Neurology, 2018, 90, 777. | Rae-Grant A. | 7.609 | 252 | —a | | 47 | Rab32 connects ER stress to mitochondrial defects in multiple sclerosis, J Neuroinflammation, 2017, 14, 19. | Haile Y. | 5.193 | 237 | 8 | | 48 | High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis, Neurology, 2017, 88, 842. | Nash R. A. | 7.609 | 219 | 21 | | 49 | Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of neurology, Neurology, 2018, 90, 789. | Rae-Grant A. | 7.609 | 217 | —a | | 50 | Vitamin D as an early predictor of multiple sclerosis activity and progression, JAMA Neurol, 2014, 71, 306. | Ascherio A. | 11.46 | 216 | 203 | | 51a | New inroads against multiple sclerosis, JAMA, 2018, 319, 9. | Lyon J. | 47.661 | 213 | 2 | | 51b | Neurofilament light chain level is a weak risk factor for the development of multiple sclerosis, Neurology, 2016, 87, 1076. | Arrambide G. | 7.609 | 213 | 20 | | 53 | Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States, Curr Med Res Opin, 2016, 32, 1783. | Bin Sawad A. | 2.665 | 209 | 3 | | 54 | Combating the spread of ineffective medical procedures: A lesson learned from multiple sclerosis, JAMA Neurol, 2017, 75, 15. | Green A. J. | 11.46 | 208 | 0 | | 55 | Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy, Neurology, 2017, 90, e12. | Barreras P. | 7.609 | 206 | 2 | | 56 | Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study, Lancet, 2014, 383, 138. | Traboulsee A. L. | 53.254 | 203 | 44 | | 57 | Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study, J Neurol Neurosurg Psychiatry, 2016, 87, 1204. | Pan G. | 7.144 | 201 | 12 | | 58 | Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics, BMC Med, 2013, 11, 205. | Morris G. | 9.088 | 197 | 54 | | 59a | Effect of smoking cessation on multiple sclerosis prognosis, JAMA Neurol, 2015, 72, 1117. | Ramanujam R. | 11.46 | 188 | 49 | | 59b | Physical activity and the incidence of multiple sclerosis, Neurology, 2016, 87, 1770. | Dorans K. | 7.609 | 188 | 3 | | 61a | Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain, Lancet, 2014, 383, 106. | Paul F. | 53.254 | 186 | 5 | | 61b | Diet and disease modification in multiple sclerosis: A nutritional epidemiology perspective, J Neurol Neurosurg Psychiatry, 2018, 89, 3. | Fitzgerald K. | 7.144 | 186 | —a | | 63 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, 2018, 17, 162. | Thompson A. J. | 27.138 | 179 | 88 | | 64 | Assessing response to interferon-β in a multicenter dataset of patients with multiple sclerosis, Neurology, 2016, 87, 134. | Sormani M. P. | 7.609 | 177 | 28 | | 65a | Disconnection as a mechanism for social cognition impairment in multiple sclerosis, Neurology, 2017, 89, 38. | Batista S. | 7.609 | 170 | 7 | | 65b | Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females, J Neurol Neurosurg Psychiatry, 2015, 86, 603. | Pedrini M. J. | 7.144 | 170 | 21 | | 67 | HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study, J Neurol Neurosurg Psychiatry, 2015, 86, 9. | Gold J. | 7.144 | 167 | 38 | | 68 | Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study, Lancet Neurol, 2017, 16, 445. | Wijnands J. M. A. | 27.138 | 164 | 14 | | 69 | Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial, Neurology, 2015, 84, 981. | Mancardi G. L. | 7.609 | 162 | 79 | | 70 | Psychiatric comorbidity is associated with disability progression in multiple sclerosis, Neurology, 2018, 90, e1316. | McKay K. A. | 7.609 | 158 | 2 | | 71 | Obesity and multiple sclerosis: a Mendelian randomization study, PLoS Med, 2016, 13, e1002053. | Mokry L. E. | 11.675 | 154 | 35 | | 72 | BCG vaccine for clinically isolated syndrome and multiple sclerosis: infections and protective immunity, Neurology, 2013, 82, 15. | Bourdette D. | 7.609 | 152 | 5 | | 73 | Efficacy of balance and eye-movement exercises for persons with multiple sclerosis (BEEMS), Neurology, 2018, 90, e797. | Hebert J. R. | 7.609 | 148 | —a | | 74 | Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial, Lancet, 2003, 362, 1517. | Zajicek J. | 53.254 | 146 | 528 | | 75 | Taste dysfunction in multiple sclerosis, J Neurol, 2016, 263, 677. | Doty R. L. | 3.783 | 145 | 5 | | 76 | Association between age at onset of multiple sclerosis and vitamin D level-related factors, Neurology, 2016, 86, 88. | Laursen J. H. | 7.609 | 144 | 7 | | 77 | Multiple sclerosis and extract of cannabis: results of the MUSEC trial, J Neurol Neurosurg Psychiatry, 2012, 83, 1125. | Zajicek J. P. | 7.144 | 141 | 95 | | 78a | Haemopoietic stem-cell transplantation for multiple sclerosis: what next?, Lancet, 2016, 388, 536. | Dörr J. | 53.254 | 139 | 2 | | 78b | Sodium intake is associated with increased disease activity in multiple sclerosis, J Neurol Neurosurg Psychiatry, 2015, 86, 26. | Farez M. F. | 7.144 | 139 | 92 | | 80a | Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses, JAMA Neurol, 2015, 72, 1132. | Hellwig K. | 11.46 | 138 | 30 | | 80b | Malignancies after mitoxantrone for multiple sclerosis A retrospective cohort study, Neurology, 2016, 86, 2203. | Martinelli V. | 7.609 | 138 | 16 | | 82 | Noninvasive tongue stimulation combined with intensive cognitive and physical rehabilitation induces neuroplastic changes in patients with multiple sclerosis: a multimodal neuroimaging study, Mult Scler J Exp Transl Clin, 2017, 3, 2055217317690561. | Leonard G. | — | 137 | 3 | | 83 | Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis, JAMA Neurol, 2018, 75, 320. | Granqvist M. | 11.46 | 136 | 7 | | 84 | Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis, Neurology, 2016, 87, 1457. | Bove R. | 7.609 | 135 | 5 | | 85a | Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis report of the guideline development Subcommittee of the American Academy of neurology, Neurology, 2014, 82, 1083. | Yadav V. | 7.609 | 134 | 64 | | 85b | The underdiagnosis of sleep disorders in patients with multiple sclerosis, J Clin Sleep Med, 2014, 10, 1025. | Brass S. D. | 3.396 | 134 | 41 | | 86b | Selection of patients with multiple sclerosis to undergo autologous hematopoietic stem cell transplantation, JAMA Neurol, 2017, 74, 392. | Racke M. K. | 11.46 | 132 | 0 | | 88 | Contribution of dietary intake to relapse rate in early pediatric multiple sclerosis, J Neurol Neurosurg Psychiatry, 2018, 89, 28. | Azary S. | 7.144 | 132 | 5 | | 89 | B-cell depletion-a frontier in monoclonal antibodies for multiple sclerosis, N Engl J Med, 2017, 376, 280. | Calabresi P. A. | 79.258 | 131 | 7 | | 90 | Vitamin D during pregnancy and multiple sclerosis: an evolving association, JAMA Neurol, 2016, 73, 498. | Greenberg B. M. | 11.46 | 125 | 4 | | 91 | Neuroendothelial NMDA receptors as therapeutic targets in experimental autoimmune encephalomyelitis, Brain, 2016, 139, 2406. | Macrez R. | 10.84 | 124 | 5 | | 92 | Pain in people with multiple sclerosis: associations with modifiable lifestyle factors, fatigue, depression, anxiety, and mental health quality of life, Front Neurol, 2017, 8, 461. | Marck C. H. | 3.508 | 122 | 0 | | 93a | Effect of low saturated fat diet in early and late cases of multiple sclerosis, Lancet, 1990, 336, 37. | Swank R. L. | 53.254 | 121 | 120 | | 93b | The contemporary spectrum of multiple sclerosis misdiagnosis: a multicenter study, Neurology, 2016, 87, 1393. | Solomon A. J. | 7.609 | 121 | 40 | | 95 | Sustained reduction of multiple sclerosis disability: new player in comparing disease-modifying treatments, Neurology, 2016, 87, 1966. | Bielekova B. | 7.609 | 119 | 1 | | 96 | Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study, Neurology, 2004, 63, 838. | Hernán M. A. | 7.609 | 117 | 202 | | 97a | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial, Lancet, 2012, 380, 1819. | Cohen J. A. | 53.254 | 115 | 516 | | 97b | Genes and environment in multiple sclerosis project: a platform to investigate multiple sclerosis risk, Ann Neurol, 2016, 79, 178. | Xia Z. | 10.244 | 115 | 14 | | 99a | Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis, N Engl J Med, 2012, 367, 1098. | Gold R. | 79.258 | 113 | 765 | | 99b | Smoking beyond multiple sclerosis diagnosis: a risk factor still worth modifying, JAMA Neurol, 2015, 72, 1105. | Goldman M. D. | 11.46 | 113 | 0 |
|
|
